Fluticasone propionate powder: Oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 2 II, 1999, Pages 267-275

  Nelson, Harold S ^a   Busse, William W ^b   Deboisblanc, Bennett P ^c   Berger, William E ^d   Noonan, Michael J ^e   Robert Webb, D ^f   Wolford, Jill P ^g   Mahajan, Puneet S ^g   Hamedani, Abbas G ^g   Shah, Tushar ^g   Harding, Stuart M ^g  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b University of Wisconsin Health   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^d Southern California Research Center   (United States)

^e Allergy Associates PC   (United States)

^f Allergy and Asthma Research Associates   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Diskus; Fluticasone propionate; Oral corticosteroid sparing

Indexed keywords

FLUTICASONE PROPIONATE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; HORMONE INHIBITION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THRUSH;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PLACEBOS; POWDERS; PREDNISONE; QUALITY OF LIFE;

EID: 0033044660     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70501-4     Document Type: Article

References (37)

1. Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, Howarth PH, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-57.
2. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health (National Heart, Lung, and Blood Institute); April 1997. NIH Publication No 97-4051.
3. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972;49:329-36.
4. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1987;58:326-30.
5. Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989;30:83-103.
6. Neirop G, Gijzel WP, Bel H, Awinderman AH, Dijkman JH. Auranofin in the treatment of steroid dependent asthma: a double-blind study. Thorax 1992;47:349-54.
7. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991;88:208-12.
8. Alexander AG, Barnes NC, Kay BA. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992;339:324-8.
9. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84(Suppl A):25-9.
10. Phillips GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84(Suppl A): 19-23.
11. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
12. Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997;10:1496-9.
13. Condemi JJ, Chervinsky P, Goldstein ME, Ford LB, Berger WE, Ayars GH, et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol 1997;100:467-74.
14. Gross GN, Wolfe JD, Noonan MJ, Pinnas JL, Pleskow WW, Nathan RA, et al. Differential effects of inhaled corticosteroids: fluticasone propionate versus triamcinolone acetonide. Am J Managed Care 1998;4:233-49.
15. Barnes NC, Hallett C, Harris TAJ. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998;92:95-104.
16. Noonan M, Chervinsky P, Busse W, Weisberg SC, Pinnas J, DeBoisblanc BP, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995;152:1467-73.
17. Okamoto LJ, Noonan M, DeBoisblanc BP, Kellerman DJ. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol 1996;76:455-61.
18. \18. Malton A, Sumby BS, Smith U. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res 1995;7:177-93.
19. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
20. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
21. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders; 1971. p. 12-7.
22. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
23. Juniper EF, Guyatt GH, William A, Griffith LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994;47:81-7.
24. Harding SM. Fluticasone propionate: pharmacology and implications for clinical practice. Adv Ther 1997;14:153-9.
25. Lacronique J, Renon D, Georges D, Henry-Amar M, Marsac J. High-dose beclomethasone: oral steroid-sparing effect in severe asthmatic patients. Eur Respir J 1991;4:807-12.
26. Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Nartin RJ, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. Ann Intern Med 1991;114:353-60.
27. Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995;8:1091-9.
28. Bernstein LI, Bernstein DI, Dubb JW, Faiferman I, Wallin B. A placebo-controlled multicenter study auranofin in the treatment of patients with corticosteroid-dependent asthma. J Allergy Clin Immunol 1996;98:317-24.
29. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:676-83.
30. Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Krai KM, Schaberg A, et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma 1996;33:265-74.
31. Rosenhall L, Lundqvist G, Adelroth E, Glennow C. Comparison between inhaled and oral corticesteroids in patients with chronic asthma. Eur J Respir Dis 1982;63(Suppl 122):154-62.
32. Nelson H, deBoisblanc B, Korenblat P. Longterm study of fluticasone propionate (FP) administered via Diskus in severe asthmatic oral corticosteroid-dependent patients [abstract], J Allergy Clin Immunol 1998;101(1 [Pt 2]):S11.
33. Li JTC, Ford LB, Chervinsky P, Weisberg SC, Kellerman DJ, Faulkner KG, et al. Fluticasone propionate powder and lack of clinically significant effects on HPA axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol. In press.
34. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
35. Smith ND. Quality of life studies from the perspective of an FDA reviewing statistician. Drug Inform J 1993;27:617-23.
36. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
37. Rutten-van Molken MPMH, Custers F, Van Doorslaer EKA, Jansen CCM, Heurman L, Maesen FPV, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995;8:888-98.